Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient

• Published in: Clinical drug investigation Vol. 38; no. 10; pp. 983 - 987
• Main Authors: Metro, Giulio, Baglivo, Sara, Siggillino, Annamaria, Ludovini, Vienna, Chiari, Rita, Rebonato, Alberto, Bellezza, Guido
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.10.2018; Springer Nature B.V
• Subjects: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents - administration & dosage; Biopsy; Cancer therapies; Carcinoma, Non-Small-Cell Lung - diagnostic imaging; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Case Report; Chemotherapy; Cloning; Dyspnea; Epidermal growth factor; ErbB Receptors - genetics; Histology; Humans; Internal Medicine; Kinases; Lung cancer; Lung Neoplasms - diagnostic imaging; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Male; Medical imaging; Medicine; Medicine & Public Health; Mutation; Mutation - genetics; Pharmacology/Toxicology; Pharmacotherapy; Piperazines - administration & dosage; Response rates; Targeted cancer therapy; Treatment Outcome; Italy
• ISSN: 1173-2563; 1179-1918
• DOI: 10.1007/s40261-018-0691-8

Osimertinib is the best treatment choice for patients with epidermal growth factor receptor ( EGFR )-mutated advanced non-small-cell lung cancer (NSCLC) whose disease progresses on a first- or second-generation EGFR-tyrosine kinase inhibitor due to acquired T790M mutation. On the other hand, there is a lack of therapeutic strategies with proven efficacy at the time of progression on osimertinib. If not administered previously, platinum-based chemotherapy can provide some clinical benefit, while immunotherapy does not seem to work in this setting. Here, we report on a unique case of response to osimertinib rechallenge after intervening chemotherapy in an EGFR T790M-positive NSCLC patient pretreated with the sequence erlotinib–osimertinib.